Filtered By:
Specialty: Cardiology
Drug: Insulin

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 191 results found since Jan 2013.

Arterial hypertension and diabetes association in the elderly
ConclusionVascular metabolic complications are serious in hypertensive elderly diabetic subjects; thus, multidisciplinary care and regular monitoring is required to detect these complications early and improve life expectancy.
Source: Archives of Cardiovascular Diseases Supplements - July 24, 2019 Category: Cardiology Source Type: research

3D fusion imaging assisted carotid artery stenting is safe and feasible.
CONCLUSIONS: Carotid stenting with 3D fusion in this pilot study was safe and feasible. 3D fusion techniques using either CTA or MRA allowed a significant reduction of contrast volume but did not reduce radiation dose or exposure time. Larger prospective studies of CAS with 3D fusion imaging in patients with renal insufficiency or mild allergy to contrast are warranted. PMID: 31203597 [PubMed - as supplied by publisher]
Source: International Angiology - June 18, 2019 Category: Cardiology Tags: Int Angiol Source Type: research

Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis
ConclusionThere is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use.
Source: American Heart Journal - May 11, 2019 Category: Cardiology Source Type: research

Carotid plaque is a predictor of major adverse cardiac and cerebrovascular events in patients undergoing coronary angiography.
Conclusions: CP is an independent predictor of MACCE in patients undergoing coronary angiography. PMID: 30932085 [PubMed - in process]
Source: Archivos de Cardiologia de Mexico - April 2, 2019 Category: Cardiology Authors: Franco-Gutiérrez R, Pérez-Pérez AJ, Franco-Gutiérrez V, Ocaranza-Sánchez R, Testa-Fernández A, López-Reboiro ML, López-López A, Santás-Álvarez M, Crespo-Leiro MG, González-Juanatey C Tags: Arch Cardiol Mex Source Type: research

Neurocognition in treatment-resistant hypertension: profile and associations with cardiovascular biomarkers
Conclusion: Neurocognitive impairments are common in adults with treatment-resistant hypertension, particularly on tests of executive function. Better neurocognition is independently associated with aerobic fitness, microvascular function, and CVRFs.
Source: Journal of Hypertension - March 29, 2019 Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research

Clinical implications of cardiovascular outcome trials in type  2 diabetes.
Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. 2019 Feb 25;: Authors: Mellbin LG, Wang A, Rydén L Abstract Cardiovascular disease (CVD) is the main reason for premature death in patients with type 2 diabetes. Hyperglycemia, the hallmark of diabetes, has long been considered the link between diabetes and CVD, and many trials focused on preventing CVD manifestations by means of tight glucose control. However, diabetes is a multifactorial disease in which, e. g., insulin resistance, endothelial dysfunction, and factors such as hypertension and dyslipidemia contrib...
Source: Herz - February 27, 2019 Category: Cardiology Tags: Herz Source Type: research

New approach to diabetes care: From blood glucose to cardiovascular disease
We describe the close relationship between diabetes, cardiovascular risk factors, and cardiovascular disease, and examine multifactorial approaches to diabetes treatment, including reducing cardiovascular risk in individuals with type 2 diabetes. Finally, we analyze new prospects for the treatment of type 2 diabetes, resulting from the development of novel antidiabetic drugs.The aim of this review is that the clinician should assume the crucial role of guiding individuals with diabetes in the control of their disease, in order to improve their quality of life and prognosis. In view of the currently available evidence, the ...
Source: Revista Portuguesa de Cardiologia - January 29, 2019 Category: Cardiology Source Type: research

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Relation between high sensitivity c-reactive protein(hs-CRP) and thromboembolic risk markers assessed by echocardiography in patients with non-valvular atrial fibrillation(NVAF)
ConclusionHigh-sensitivity C-reactive protein( hs-CRP) ≥4.5 mg/dl level is suggested as inflammatory marker to predict the risk of thromboembolism in patients with non-valvular AF.
Source: Journal of Indian College of Cardiology - November 27, 2018 Category: Cardiology Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Abstract Patients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the new class of glucose-lowering medications that increase urinary glucose excretion, thus improving glycemic control, independent of insulin. The recently p...
Source: Indian Heart J - November 1, 2018 Category: Cardiology Authors: Pancholia AK Tags: Indian Heart J Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research

The role of hypoglycaemia on provoking tachyarrhythmias in patients with DMT2 , paroxysmal atrial fibrillation (pAfib) and ischemic stroke
Aim: To study the frequency of hypoglycaemia and its correlation tachyarrythmia in patients with DMT2 (on treatment with insulin or oral medication), pAfib (receiving anticoagulation) and ischemic stroke.
Source: Atherosclerosis - August 1, 2018 Category: Cardiology Authors: I.L. Matsoukis, K. Kanellopoulou, T. Athanasopoulou, A. Ganotopoulou, N. Zimpounoumi, C. Triantafillopoulou, D. Klonos, L. Skorda, A. Sianni Source Type: research

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
Conclusions -In IRIS, with surveillance and dose adjustments, pioglitazone did not increase risk of HF, and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00091949. PMID: 29934374 [PubMed - as supplied by publisher]
Source: Circulation - June 22, 2018 Category: Cardiology Authors: Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association.
cial Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council Abstract South Asians (from Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri Lanka) make up one quarter of the world's population and are one of the fastest-growing ethnic groups in the United States. Although native South Asians share genetic and cultural risk factors with South Asians abroad, South Asians in the United States can differ in socioeconomic status, education, healthcare behaviors, attitudes, and health in...
Source: Circulation - May 24, 2018 Category: Cardiology Authors: Volgman AS, Palaniappan LS, Aggarwal NT, Gupta M, Khandelwal A, Krishnan AV, Lichtman JH, Mehta LS, Patel HN, Shah KS, Shah SH, Watson KE, American Heart Association Council on Epidemiology and Prevention; Cardiovascular Disease and Stroke in Women and Sp Tags: Circulation Source Type: research

Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusions In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research